Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCHE | P06276 | 2/20 | 0.52 |
| ▸ | ACHE | P22303 | 2/20 | 0.52 |
| ▸ | BACE1 | P56817 | 2/20 | 0.52 |
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.51 |
| ▸ | CCR3 | P51677 | 1/20 | 0.49 |
| ▸ | SLC6A12 | P48065 | 1/20 | 0.48 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.48 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.48 |
| ▸ | TACR1 | P25103 | 1/20 | 0.48 |
| ▸ | DRD2 | P14416 | 1/20 | 0.47 |
| ▸ | HTR2A | P28223 | 1/20 | 0.47 |
| ▸ | HTR2C | P28335 | 1/20 | 0.47 |
| ▸ | HTR2B | P41595 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5974931 | 0.92 | CCR3 (0.57) | ACHESIGMAR1CCR3DRD2HTR2A | |
| SCHEMBL5975118 | 0.92 | CCR3 (0.57) | ACHESIGMAR1CCR3DRD2HTR2A | |
| SCHEMBL5974936 | 0.92 | CCR3 (0.57) | ACHESIGMAR1CCR3DRD2HTR2A | |
| Hydrochloric Acid SCHEMBL6660125 | 0.90 | CCR3 (0.55) | ACHESIGMAR1CCR3DRD2HTR2A | |
| SCHEMBL5974372 | 0.87 | LMNA (0.55) | BCHEACHEBACE1SIGMAR1CCR3 | |
| SCHEMBL5974378 | 0.87 | LMNA (0.55) | BCHEACHEBACE1SIGMAR1CCR3 | |
| SCHEMBL3262678 | 0.82 | ATM (0.54) | BCHEACHEBACE1SIGMAR1CCR3 | |
| SCHEMBL3262675 | 0.82 | ATM (0.54) | BCHEACHEBACE1SIGMAR1CCR3 | |
| SCHEMBL31288163 | 0.79 | ACHE (0.53) | ACHESIGMAR1CCR3DRD2HTR2A | |
| SCHEMBL27596453 | 0.79 | ACHE (0.49) | ACHESIGMAR1CCR3DRD2HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1928829-A1 | PIPERIDINE DERIVATIVES AS ANTAGONISTS OF THE CC CHEMOKINE RECEPTOR CCR1 AND THEIR USE AS ANTI-INFLAMMATORY AGENTS | Schering Aktiengesellschaft (DE) | 2008-06-11 | — | — | EP | disclosed |
| US-20060167044-A1 | Piperidine derivatives and their use as anti-inflammatory agents | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2006-07-27 | — | — | US | disclosed |
| WO-2006066948-A1 | PIPERIDINE DERIVATIVES AS ANTAGONISTS OF THE CC CHEMOKINE RECEPTOR CCR1 AND THEIR USE AS ANTI-INFLAMMATORY AGENTS | SCHERING AKTIENGESELLSCHAFT (DE) | 2006-06-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060167044-A1 | Piperidine derivatives and their use as anti-inflammatory agents | CCR1, CCR2, CCR3 | BCHE 2843/4885ACHE 2240/4885BACE1 4238/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.